PHARMACEUITICAL &

HEALTHCARE IN INDIA
SECTOR OVERVIEW
India Ranks
$38 Bn*
Baddi
1st Largest manufacturer Market Size
of Generics Pantnagar
NCR Haridwar Sikkim

12.89%
Expected CAGR
Ahmedabad Ankleshwar
2015-20
Largest Pharmaceuticals & Vapi, Vadodara

2nd Biotechnology talent pool

with Highest FDA approved Tarapur Aurangabad
$15.9 Bn
Mumbai Pune
plants Hyderabad - Medak FDI between
Pharmaceuticals Clusters April’00 –
March’19
Goa Vishakhapatnam Captive R& D Units
Bengaluru
Mysore Contract R & D Units USD
Chennai
Established Bulk Drug Cluster 19.13 bn
3rd Largest in terms of Volume
Puducherry
Established Formulations
Cluster
Exports in
FY 18-19
Emerging Bulk Drug Cluster
Emerging Formulation Cluster
DEMAND SUPPLY DRIVERS
GROWING DEMAND LIMITED SUPPLY

RISING LIFESTYLE DISEASES LACK OF SKILLED SERVICE PROVIDERS

NCDs contribute to: 0.7 physicians per 1000 population
a) 50% of all disease burden
b) 60% of all deaths
LIFE EXPECTANCY SHORTAGE OF HOSPITAL BEDS
> 70 years by 2022 hence more 0.8 beds per 1000 people
healthcare services required
DEMAND-
SUPPLY
INCREASING DISPOSABLE INCOME LOW PUBLIC HEALTH EXPENDITURE
8% to earn >US$ 12,000 p.a.
DEFICIT
<4% GDP spent on healthcare

INSURANCE COVERAGE NASCENT MEDICAL DEVICE INDUSTRY

$ 20% Indians covered; expected to rise
with rising incomes and urbanization
Importing > 80% of sophisticated
devices; Limited R&D Capacity (
Mismatch of actual skill required and
its demand)
LIFESCIENCE CLUSTERS
New Delhi
• DBT, DST, CSIR, DP, ICMR, ICAR Lucknow
• Translational Health Sciences Cluster • CDRI, IITR, CIMAP, NBRI
• National Institute of Immunology • Lucknow Biotech Park
• ICGEB
• Institute of Genomics & Integrative
Biology Kolkata
• National Brain Research Center • Indian Inst. Of Chemical Technology
• JNU, Delhi University • Centre for Cellular & Molecular Biology
• Centre for DNA Fingerprinting & Diag.
• National Institute of Nutrition, ICRISAT
Vadodara • Univ. of Hyd, Osmania
• PERD, NIPER • IKP Knowledge Park, SP Biotech Park
• Savli Biotech Park • AIBA, FABA
• Proposed Biotech Park in
Ahmedabad
• MS Univ Baroda
Hyderabad
• Indian Inst. Of Chemical Technology
Mumbai
• Centre for Cellular & Molecular Biology
• TIFR
• Centre for DNA Fingerprinting & Diag.
• IIT Bombay, Univ of Mumbai
• National Institute of Nutrition, ICRISAT
• National Chemical Lab
• Univ. of Hyd, Osmania
• National Center for Cell Sciences
• IKP Knowledge Park, SP Biotech Park
• Pune University, IISER
• AIBA, FABA
• International Biotech Park

Bengaluru Chennai
• Indian Institute of Science • Anna University
• National Center for Biological Sciences • IIT Madras
• JN Center for Advanced Scientific Research • TICEL Biotech Park
• University of Agricultural Sciences • Women’s Biotech Park
• Stem Cell Institute
• IBAB, ABLE
Overview of Pharma Exports
SUB-SECTOR OVERVIEW
Bio-Industrials Bio-IT • Bio-Pharma constitutes Biologics/ Therapeutics, Vaccines, Insulin and
8%, $4 Bn 1%, >$1 Bn Regenerative Medicine
Bio-
Pharma • Expected CAGR (2018-25): >25%

• Bio-Services refer to research-based contract, manufacturing

contracts and clinical research contracts
Bio-Services Bio-
Services • Expected CAGR (2018-25): >25%
14%, <$7 Bn

• Bio-Agri constitutes genetically modified crops and secondary

agriculture including bio-pesticides and bio-fertilizers
Bio-Pharma Bio-Agri • Expected CAGR (2018-25): >25%
56%,
Bio-Agri 21%, $28 Bn
$11 Bn • Bio-Industrials constitutes bio-fuels, industrial enzymes and bio-
polymers
Bio-
Industry • Expected CAGR (2018-25): 15-22%

• An interplay between biology and information technology, Bio-IT

includes Bio-Informatics, Genomics & Precision Medicine and Big Data
Bio-IT • Expected CAGR (2018-25): >10%
PHARMA BIO-TECH SUB-SECTOR OVERVIEW
API/BULK DRUGS
• globally; 20% of global exports in
>500 APIs manufactured in India
• Export to 150 countries
• Advantage – Chemical Synthesis &
Reverse Engineering
• World Leader in DMFs
• •
8% of global API industry (2017) in
India
• Global API market to grow by 6.6%
to USD 238.8 Bn by 2025
GENERICS BIO-SIMILARS
• Largest provider of Generic Drugs
• Globally USD 70 Billion biologic
drugs will go off patent in 2016-
terms of volume
20
• 40% of US & 30% of EU generic drugs
market catered from India
•
c
Allocation of USD 70 Mn for local
• 2nd Largest ANDAs
players to develop Bio- similars
• 50+ approved Biosimilar products in
• Multiple drugs going off patent in
the US and other countries India
Domestic generic drug market
$4T
2025
expected to reach USD 27.9 Billion in •Domestic Market expected to reach
2020
• Increased demand from rural market USD 40 Billion by 2030
PHARMA BIO-TECH SUB-SECTOR OVERVIEW
CONTRACT
MANUFACTURING
• 1000+ Players
• Regulatory and Quality Compliant
facilities
• Potential Cost savings of 30-40%
compared to Western markets
US$ 85 bn worth of drugs expected to go
off patent between 2012-20
CONTRACT RESEARCH
(CLINICAL TRIALS)
• 600,000+ English speaking skilled
investigators
• 1.3 billion population with
diverse ethnic backgrounds
• Increased Investment in
Hospitals
Indian clinical trials market size is
expected to reach USD 3.15 billion by
2025
VACCINES/ARV
• 80% of global ARVs to combat AIDS
supplied by Indian firms
• Export to 150 countries
c
• Increased R&D investment and
assistance by govt agencies
• Universal Immunization program
$4T
2025
Global Vaccines market to reach $57.50
Bn
 Thank you
VANIJ INDIA
Your India Procurement Partners

E-55, Lower Ground Floor, Kalkaji

New Delhi – 110019

+91-8920814683
info@vanijindia.com